Chitosan Nanoparticles for Intranasal Drug Delivery-Reference-Cited by-同舟云学术

Chitosan Nanoparticles for Intranasal Drug Delivery

Published:2024-05-31 Issue:6 Volume:16 Page:746
ISSN:1999-4923
Container-title:Pharmaceutics
language:en
Short-container-title:Pharmaceutics

Author:

Omidian Hossein¹^ORCID,Gill Erma J.¹^ORCID,Dey Chowdhury Sumana¹^ORCID,Cubeddu Luigi X.¹^ORCID

Affiliation:

1. Barry and Judy Silverman College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL 33328, USA

Abstract

This manuscript explores the use of nanostructured chitosan for intranasal drug delivery, targeting improved therapeutic outcomes in neurodegenerative diseases, psychiatric care, pain management, vaccination, and diabetes treatment. Chitosan nanoparticles are shown to enhance brain delivery, improve bioavailability, and minimize systemic side effects by facilitating drug transport across the blood–brain barrier. Despite substantial advancements in targeted delivery and vaccine efficacy, challenges remain in scalability, regulatory approval, and transitioning from preclinical studies to clinical applications. The future of chitosan-based nanomedicines hinges on advancing clinical trials, fostering interdisciplinary collaboration, and innovating in nanoparticle design to overcome these hurdles and realize their therapeutic potential.

Publisher

MDPI AG

Link

https://www.mdpi.com/1999-4923/16/6/746/pdf

Reference129 articles.

1. Sinko, P. (2010). Martin’s Physical Pharmacy and Pharmaceutical Sciences, Lippincott Williams & Wilkins. [6th ed.].

2. Mastropietro, D.J., Park, K., and Omidian, H. (2017). Comprehensive Biomaterials II, Elsevier.

3. Mitra, A.K., Kwarta, D., and Vadlapudi, A.D. (2014). Drug Delivery, Jones & Bartlett Learning.

4. Sheikh, F.A. (2021). Engineering Materials for Stem Cell Regeneration, Springer.

5. Intranasal delivery of chitosan decorated PLGA core/shell nanoparticles containing flavonoid to reduce oxidative stress in the treatment of Alzheimer’s disease;Dhas;J. Drug Deliv. Sci. Technol.,2021